A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice

Research output: Contribution to journalArticle

Standard

A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice. / van Staa, TP; Setakis, E; di Tanna, GL; Lane, Deirdre; Lip, Gregory.

In: Journal of Thrombosis and Haemostasis, Vol. 9, No. 1, 01.01.2011, p. 39-48.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{52526e0a019b481aa0fb5bfccebc97e5,
title = "A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice",
abstract = "Background: Anticoagulation management of patients with atrial fibrillation (AF) should be tailored individually on the basis of ischemic stroke risk. The objective of this study was to compare the predictive ability of 15 published stratification schemes for stroke risk in actual clinical practice in the UK. Methods: AF patients aged >= 18 years in the General Practice Research Database, which contains computerized medical records, were included. The c-statistic was estimated to determine the predictive ability for stroke for each scheme. Outcomes included stroke, hospitalizations for stroke, and death resulting from stroke (as recorded on death certificates). Results: The study cohort included 79 844 AF patients followed for an average of 4 years (average of 2.4 years up to the start of warfarin therapy). All risk schemes had modest discriminatory ability in AF patients, with c-statistics for predicting events ranging from 0.55 to 0.69 for strokes recorded by the general practitioner or in hospital, from 0.56 to 0.69 for stroke hospitalizations, and from 0.56 to 0.78 for death resulting from stroke as reported on death certificates. The proportion of patients assigned to individual risk categories varied widely across the schemes, with the proportion categorized as moderate risk ranging from 12.7% (CHA(2)DS(2)-VASc) to 61.5% (modified CHADS(2)). Low-risk subjects were truly low risk (with annual stroke events <0.5%) with the modified CHADS(2), National Institute for Health and Clinical Excellence and CHA(2)DS(2)-VASc schemes. Conclusion: Current published risk schemes have modest predictive value for stroke. A new scheme (CHA(2)DS(2)-VASc) may discriminate those at truly low risk and minimize classification of subjects as intermediate/moderate risk. This approach would simplify our approach to stroke risk stratification and improve decision-making for thromboprophylaxis in patients with AF.",
keywords = "risk stratification schemes, stroke, atrial fibrillation",
author = "{van Staa}, TP and E Setakis and {di Tanna}, GL and Deirdre Lane and Gregory Lip",
year = "2011",
month = jan,
day = "1",
doi = "10.1111/j.1538-7836.2010.04085.x",
language = "English",
volume = "9",
pages = "39--48",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice

AU - van Staa, TP

AU - Setakis, E

AU - di Tanna, GL

AU - Lane, Deirdre

AU - Lip, Gregory

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Anticoagulation management of patients with atrial fibrillation (AF) should be tailored individually on the basis of ischemic stroke risk. The objective of this study was to compare the predictive ability of 15 published stratification schemes for stroke risk in actual clinical practice in the UK. Methods: AF patients aged >= 18 years in the General Practice Research Database, which contains computerized medical records, were included. The c-statistic was estimated to determine the predictive ability for stroke for each scheme. Outcomes included stroke, hospitalizations for stroke, and death resulting from stroke (as recorded on death certificates). Results: The study cohort included 79 844 AF patients followed for an average of 4 years (average of 2.4 years up to the start of warfarin therapy). All risk schemes had modest discriminatory ability in AF patients, with c-statistics for predicting events ranging from 0.55 to 0.69 for strokes recorded by the general practitioner or in hospital, from 0.56 to 0.69 for stroke hospitalizations, and from 0.56 to 0.78 for death resulting from stroke as reported on death certificates. The proportion of patients assigned to individual risk categories varied widely across the schemes, with the proportion categorized as moderate risk ranging from 12.7% (CHA(2)DS(2)-VASc) to 61.5% (modified CHADS(2)). Low-risk subjects were truly low risk (with annual stroke events <0.5%) with the modified CHADS(2), National Institute for Health and Clinical Excellence and CHA(2)DS(2)-VASc schemes. Conclusion: Current published risk schemes have modest predictive value for stroke. A new scheme (CHA(2)DS(2)-VASc) may discriminate those at truly low risk and minimize classification of subjects as intermediate/moderate risk. This approach would simplify our approach to stroke risk stratification and improve decision-making for thromboprophylaxis in patients with AF.

AB - Background: Anticoagulation management of patients with atrial fibrillation (AF) should be tailored individually on the basis of ischemic stroke risk. The objective of this study was to compare the predictive ability of 15 published stratification schemes for stroke risk in actual clinical practice in the UK. Methods: AF patients aged >= 18 years in the General Practice Research Database, which contains computerized medical records, were included. The c-statistic was estimated to determine the predictive ability for stroke for each scheme. Outcomes included stroke, hospitalizations for stroke, and death resulting from stroke (as recorded on death certificates). Results: The study cohort included 79 844 AF patients followed for an average of 4 years (average of 2.4 years up to the start of warfarin therapy). All risk schemes had modest discriminatory ability in AF patients, with c-statistics for predicting events ranging from 0.55 to 0.69 for strokes recorded by the general practitioner or in hospital, from 0.56 to 0.69 for stroke hospitalizations, and from 0.56 to 0.78 for death resulting from stroke as reported on death certificates. The proportion of patients assigned to individual risk categories varied widely across the schemes, with the proportion categorized as moderate risk ranging from 12.7% (CHA(2)DS(2)-VASc) to 61.5% (modified CHADS(2)). Low-risk subjects were truly low risk (with annual stroke events <0.5%) with the modified CHADS(2), National Institute for Health and Clinical Excellence and CHA(2)DS(2)-VASc schemes. Conclusion: Current published risk schemes have modest predictive value for stroke. A new scheme (CHA(2)DS(2)-VASc) may discriminate those at truly low risk and minimize classification of subjects as intermediate/moderate risk. This approach would simplify our approach to stroke risk stratification and improve decision-making for thromboprophylaxis in patients with AF.

KW - risk stratification schemes

KW - stroke

KW - atrial fibrillation

U2 - 10.1111/j.1538-7836.2010.04085.x

DO - 10.1111/j.1538-7836.2010.04085.x

M3 - Article

VL - 9

SP - 39

EP - 48

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 1

ER -